Study #2019-0125
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study To Evaluate The Safety And Efficacy Of Alpha-1 Antitrypsin For The Prevention Of Graft-Versus Host Disease In Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study)
MD Anderson Study Status
Not Accepting
Treatment Agent
Alpha-1 antitrypsin (AAT), Placebo
Description
This study is a Phase 2/3 prospective, double-blind, randomized, multi-center, placebo-controlled study for prevention of acute GVHD (aGVHD) in subjects undergoing an allogeneic hematopoietic cell transplant (HCT).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute-graft-versus-host Disease
Study phase:
Phase II/III
Physician name:
Amin Alousi
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.